Biochemical recurrence after localized treatment

被引:19
作者
Amling, Christopher L. [1 ]
机构
[1] Univ Alabama Birmingham, Div Urol, Birmingham, AL 35294 USA
关键词
D O I
10.1016/j.ucl.2005.12.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The quoted incidence of biochemical recurrence (BCR) after localized treatment varies significantly and depends on numerous well-known prognostic factors; however, it likely occurs in at least 30%-40% of patients who receive localized treatment. Because the clinical significance of BCR is often unclear, and depends in many cases on unknown factors, it is difficult to select the best treatment and determine when best to institute that therapy. This review examines some of the issues associated with BCR and attempts to shed some light on this common but controversial clinical scenario. Some treatment strategies discussed in this article include salvage radiotherapy after radical prostatectomy, salvage therapy after radiotherapy, and hormonal therapy.
引用
收藏
页码:147 / +
页数:14
相关论文
共 79 条
[11]   Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy [J].
Lange, PH .
JOURNAL OF UROLOGY, 1998, 159 (01) :177-178
[12]   Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer [J].
Cannon, GM ;
Walsh, PC ;
Partin, AW ;
Pound, CR .
UROLOGY, 2003, 62 (6B) :2-8
[13]   Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy [J].
Cher, ML ;
Bianco, FJ ;
Lam, JS ;
Davis, LP ;
Grignon, DJ ;
Sakr, WA ;
Banerjee, M ;
Pontes, JE ;
Wood, DP .
JOURNAL OF UROLOGY, 1998, 160 (04) :1387-1391
[14]   Results of salvage cryoablation of the prostate after radiation: Identifying predictors of treatment failure and complications [J].
Chin, JL ;
Pautler, SE ;
Mouraviev, V ;
Touma, N ;
Moore, K ;
Downey, DB .
JOURNAL OF UROLOGY, 2001, 165 (06) :1937-1941
[15]   Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer [J].
D'Amico, AV ;
Cote, K ;
Loffredo, M ;
Renshaw, AA ;
Schultz, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4567-4573
[16]   Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure [J].
D'Amico, AV ;
Chen, MH ;
Roehl, KA ;
Catalona, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4975-4979
[17]   Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy [J].
D'Amico, AV ;
Renshaw, AA ;
Sussman, B ;
Chen, MH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (04) :440-447
[18]   Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].
D'Amico, AV ;
Moul, JW ;
Carroll, PR ;
Sun, L ;
Lubeck, D ;
Chen, MH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383
[19]   Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy [J].
D'Amico, AV ;
Chen, MH ;
Roehl, KA ;
Catalona, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :125-135
[20]  
DAMICO AV, 1993, CANCER-AM CANCER SOC, V72, P2638, DOI 10.1002/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO